Skip to search formSkip to main contentSkip to account menu

HMN-214

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression.
2004
2004
A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors
3034 Background: HMN-176 is a stilbazole derivative with potent antitumor activity in preclinical models. HMN-176 interferes with… 
2004
2004
A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors.
3034 Background: HMN-176 is a stilbazole derivative with potent antitumor activity in preclinical models. HMN-176 interferes with… 
2004
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Highly Cited
2003
Highly Cited
2003
HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y.
HMN-176 ((E)-4-[[2-N-[4-methoxybenzenesulfonyl]amino]stilbazole]1-oxide) is an active metabolite of HMN-214 ((E)-4-[2-[2-(N… 
2003
2003
Factor NF-Y Multidrug-Resistant Cells by Targeting the Transcription Agent HMN-214 , Restores Chemosensitivity to HMN-176 , an Active Metabolite of the Synthetic Antitumor
HMN-176 ((E)-4-{[2-N-[4-methoxybenzenesulfonyl]amino]stilbazole}1oxide) is an active metabolite of HMN-214 ((E)-4-{2-[2-(N-acetyl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)